Company
Headquarters: Turku, Finland
Employees: 24
CEO: Dr. Markku Tapani Jalkanen
€119.1 Million
EUR as of July 1, 2024
US$127.9 Million
Company | Market Cap (USD) |
---|---|
Novo Nordisk | $622.07 B |
Vertex Pharmaceuticals Incorporated | $113.24 B |
CSL Limited | $95.75 B |
Regeneron Pharmaceuticals, Inc. | $76.33 B |
Marinomed Biotech AG | $56.13 B |
Company | Market Cap (USD) |
---|---|
Lilly | $689.42 B |
Novo Nordisk | $622.07 B |
UnitedHealth Group | $487.54 B |
Johnson & Johnson | $353.05 B |
AbbVie | $301.60 B |
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company develops a pipeline of immune modulation based proprietary drug candidates for unmet need, including immuno-oncology, and organ protection and regenerative medicine. Its lead product candidates are Traumakine, an intravenous interferon beta-1a therapy for the treatment of acute respiratory distress syndrome, COVID-19, acute kidney injury, cardiac protection, solid organ transplant, and ischemia reperfusion injury; and Bexmarilimab, a novel precision cancer immunotherapy candidate for treating solid tumors, non-small cell lung carcinoma, and hematological malignancies. The company also develops Haematokine, a new chemical entity AOC3 inhibitor for the treatment of hematological malignancies and bone marrow. Faron Pharmaceuticals Oy was founded in 2003 and is headquartered in Turku, Finland.
Last Financial Reports Date | Dec. 31, 2023 |
Revenue TTM | €0 |
EBITDA | €-28,371,000 |
Gross Profit TTM | €0 |
Profit Margin | 0.00% |
Operating Margin | 0.00% |
Quarterly Revenue Growth | % |
Faron Pharmaceuticals OY has the following listings and related stock indices.
Stock: OMXH: FARON wb_incandescent
Stock: LSE: FARN wb_incandescent